Preparations for a December trial between Merck Sharp & Dohme Corporation and Wyeth over four patents for the pneumococcal disease vaccine are underway, and a panel of experts will feature prominently in the high-stakes hearing over the world’s best-selling vaccine.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au